Literature DB >> 23348427

Neurodevelopmental outcomes of umbilical cord blood transplantation in metachromatic leukodystrophy.

Holly R Martin1, Michele D Poe, James M Provenzale, Joanne Kurtzberg, Adam Mendizabal, Maria L Escolar.   

Abstract

Metachromatic leukodystrophy (MLD) is an inherited demyelinating disease that causes progressive neurologic deterioration, leading to severe motor disability, developmental regression, seizures, blindness, deafness, and death. The disease presents as a late-infantile, juvenile, or adult form. Hematopoietic stem cell transplantation has been shown to slow disease progression. The purpose of this longitudinal study was to evaluate long-term treatment outcomes after unrelated donor umbilical cord blood (UCB) transplantation in pediatric patients according to disease burden and age at onset (ie, late-infantile versus juvenile). Engraftment, survival, treatment-related toxicity, graft-versus-host disease, neurophysiologic measures, and neurodevelopmental function were assessed. To evaluate whether signal intensity abnormalities on magnetic resonance imaging (ie, modified Loes scores) predict post-transplant cognitive and gross motor development, a general linear mixed model was fit to the data. Twenty-seven patients underwent transplantation after myeloablative chemotherapy; 24 patients engrafted after the initial transplantation. Seven patients died of infection, regimen-related toxicity, or disease progression. Twenty patients (6 with late-infantile onset and 14 with juvenile onset) were followed for a median of 5.1 years (range, 2.4 to 14.7). We found that patients with motor function symptoms at the time of transplant did not improve after transplantation. Brainstem auditory evoked responses, visual evoked potentials, electroencephalogram, and/or peripheral nerve conduction velocities stabilized or improved in juvenile patients but continued to worsen in most patients with the late-infantile presentation. Pretransplant modified Loes scores were highly correlated with developmental outcomes and predictive of cognitive and motor function. Children who were asymptomatic at the time of transplantation benefited most from the procedure. Children with juvenile onset and minimal symptoms showed stabilization or deterioration of motor skills but maintained cognitive skills. Overall, children with juvenile onset had better outcomes than those with late-infantile onset. As in other leukodystrophies, early intervention correlated with optimal outcomes. We conclude that UCB transplantation benefits children with presymptomatic late-infantile MLD or minimally symptomatic juvenile MLD.
Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23348427     DOI: 10.1016/j.bbmt.2013.01.010

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  35 in total

Review 1.  Mesenchymal stem cells as cellular vectors for pediatric neurological disorders.

Authors:  Donald G Phinney; Iryna A Isakova
Journal:  Brain Res       Date:  2014-05-22       Impact factor: 3.252

Review 2.  Gene therapy for metachromatic leukodystrophy.

Authors:  Jonathan B Rosenberg; Stephen M Kaminsky; Patrick Aubourg; Ronald G Crystal; Dolan Sondhi
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 3.  Hematopoietic stem cell transplantation in the leukodystrophies: a systematic review of the literature.

Authors:  Patricia L Musolino; Troy C Lund; Jessica Pan; Maria L Escolar; Asif M Paker; Christine N Duncan; Florian S Eichler
Journal:  Neuropediatrics       Date:  2014-01-23       Impact factor: 1.947

4.  Disease specific therapies in leukodystrophies and leukoencephalopathies.

Authors:  Guy Helman; Keith Van Haren; Joshua L Bonkowsky; Genevieve Bernard; Amy Pizzino; Nancy Braverman; Dean Suhr; Marc C Patterson; S Ali Fatemi; Jeff Leonard; Marjo S van der Knaap; Stephen A Back; Stephen Damiani; Steven A Goldman; Asako Takanohashi; Magdalena Petryniak; David Rowitch; Albee Messing; Lawrence Wrabetz; Raphael Schiffmann; Florian Eichler; Maria L Escolar; Adeline Vanderver
Journal:  Mol Genet Metab       Date:  2015-02-07       Impact factor: 4.797

Review 5.  Concise Review: Stem Cell-Based Treatment of Pelizaeus-Merzbacher Disease.

Authors:  M Joana Osorio; David H Rowitch; Paul Tesar; Marius Wernig; Martha S Windrem; Steven A Goldman
Journal:  Stem Cells       Date:  2016-11-23       Impact factor: 6.277

Review 6.  Current Perspective of Stem Cell Therapy in Neurodegenerative and Metabolic Diseases.

Authors:  Ajay Kumar; Karthikeyan Narayanan; Ravi Kumar Chaudhary; Sachin Mishra; Sundramurthy Kumar; Kumar Jayaseelan Vinoth; Parasuraman Padmanabhan; Balázs Gulyás
Journal:  Mol Neurobiol       Date:  2016-11-04       Impact factor: 5.590

Review 7.  Glial progenitor cell-based treatment of the childhood leukodystrophies.

Authors:  M Joana Osorio; Steven A Goldman
Journal:  Exp Neurol       Date:  2016-05-08       Impact factor: 5.330

Review 8.  Lysosomal Leukodystrophies Lysosomal Storage Diseases Associated With White Matter Abnormalities.

Authors:  Gustavo H B Maegawa
Journal:  J Child Neurol       Date:  2019-02-13       Impact factor: 1.987

Review 9.  Emerging treatments for pediatric leukodystrophies.

Authors:  Guy Helman; Keith Van Haren; Maria L Escolar; Adeline Vanderver
Journal:  Pediatr Clin North Am       Date:  2015-04-08       Impact factor: 3.278

Review 10.  Cell therapy for diverse central nervous system disorders: inherited metabolic diseases and autism.

Authors:  Jessica M Sun; Joanne Kurtzberg
Journal:  Pediatr Res       Date:  2017-11-08       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.